Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancerChristopher G. Willett, Dushyant V. Sahani, Sanjeeva P. Kalva et al.|Nature Medicine|2004Cited by 2k
Colon CancerPaul F. Engstrom, Christopher G. Willett|Journal of the National Comprehensive Cancer Network|2009Cited by 684
Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II StudyChristopher G. Willett, Dan G. Duda, Emmanuelle di Tomaso et al.|Journal of Clinical Oncology|2009Cited by 507
Rectal CancerPaul F. Engstrom, Christopher G. Willett|Journal of the National Comprehensive Cancer Network|2009Cited by 441
Surrogate Markers for Antiangiogenic Therapy and Dose-Limiting Toxicities for Bevacizumab With Radiation and Chemotherapy: Continued Experience of a Phase I Trial in Rectal Cancer PatientsChristopher G. Willett, Gregory Y. Lauwers, Yves Boucher et al.|Journal of Clinical Oncology|2005Cited by 419